| Company/Division name | Genentech |
| Parent company | Roche |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2031 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 750 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Hillsboro |
| State(s) reshored to: | OR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceutical drugs |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Image/brand, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
